Literature DB >> 6352387

Graft-versus-host disease of the intestine: a protein losing enteropathy characterized by fecal alpha 1-antitrypsin.

S A Weisdorf, L M Salati, J A Longsdorf, N K Ramsay, H L Sharp.   

Abstract

Severe hypoproteinemia often accompanies the development of graft-versus-host disease of the intestine in allogeneic bone marrow transplant patients. To determine whether or not protein loss occurs across the intestinal mucosa in this severe diarrheal illness, we measured fecal alpha 1-antitrypsin once per week in 24-h stool specimens from 25 consecutive patients during hospitalization for bone marrow transplantation. The mean alpha 1-antitrypsin concentration and serum clearance for these patients before transplantation were below 2.6 mg/g stool and 13.0 ml/day (upper limits for normals). Values for all patients increased moderately after pretransplant conditioning. Values for patients who did not develop graft-versus-host disease of the intestine returned to baseline levels; however, those for patients with graft-versus-host disease of the intestine became markedly and persistently elevated (concentration ranged from 16.6 to 51.1 mg/g, clearance from 66.6 to 384.5 ml/day). We conclude that mucosal protein exudation contributes to the hypoproteinemia of graft-versus-host disease of the intestine and that measurement of fecal alpha 1-antitrypsin can be used as a marker for this disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6352387

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  16 in total

Review 1.  Graft-versus-host disease of the intestine.

Authors:  G J Cox; G B McDonald
Journal:  Springer Semin Immunopathol       Date:  1990

Review 2.  Gastrointestinal problems in the immunosuppressed patient.

Authors:  V Aggarwal; M D Williams; S V Beath
Journal:  Arch Dis Child       Date:  1998-01       Impact factor: 3.791

Review 3.  Acute graft-versus-host disease of the gut: considerations for the gastroenterologist.

Authors:  Steven Naymagon; Leonard Naymagon; Serre-Yu Wong; Huaibin Mabel Ko; Anne Renteria; John Levine; Jean-Frederic Colombel; James Ferrara
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-27       Impact factor: 46.802

4.  Corticosteroid replacement by ruxolitinib in patients with acute GVHD experiencing severe steroid-induced side effects.

Authors:  Elizabeth A de Kort; Suzanne van Dorp; Nicole M A Blijlevens; Walter J F M van der Velden
Journal:  Bone Marrow Transplant       Date:  2019-04-10       Impact factor: 5.483

5.  Enteral nutrition after bone marrow transplantation.

Authors:  A Papadopoulou; A MacDonald; M D Williams; P J Darbyshire; I W Booth
Journal:  Arch Dis Child       Date:  1997-08       Impact factor: 3.791

6.  Screening laboratory tests for Crohn's disease.

Authors:  D W Thomas; F R Sinatra
Journal:  West J Med       Date:  1989-02

7.  α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.

Authors:  John M Magenau; Steven C Goldstein; Dan Peltier; Robert J Soiffer; Thomas Braun; Attaphol Pawarode; Mary M Riwes; Maggi Kennel; Joseph H Antin; Corey S Cutler; Vincent T Ho; Edwin P Alyea; Brian L Parkin; Gregory A Yanik; Sung Won Choi; Eli C Lewis; Charles A Dinarello; John Koreth; Pavan Reddy
Journal:  Blood       Date:  2018-02-02       Impact factor: 22.113

Review 8.  The role of parenteral nutrition in acute leukemia.

Authors:  Nicole B Jacobson; Neha Parekh; Matt Kalaycio
Journal:  Curr Hematol Malig Rep       Date:  2006-09       Impact factor: 3.952

9.  How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver.

Authors:  George B McDonald
Journal:  Blood       Date:  2016-01-04       Impact factor: 22.113

10.  Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation.

Authors:  Andrew R Rezvani; Barry E Storer; Rainer F Storb; Marco Mielcarek; David G Maloney; Brenda M Sandmaier; Paul J Martin; George B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-30       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.